NCT06389123View on ClinicalTrials.gov

Molecularly Targeted Theranostic Approach for the Detection and Treatment of Metastatic Carcinomas

PHASE1RecruitingINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

April 1, 2024

Primary Completion Date

March 31, 2027

Study Completion Date

March 31, 2028

Conditions
Metastatic Cancer
Interventions
DRUG

[68Ga]Ga DOTA-5G and [177Lu]Lu DOTA-ABM-5G.

Patients will be undergo \[68Ga\]Ga DOTA-5G PET/CT scans to confirm eligibility for the \[177Lu\]Lu DOTA-ABM-5G therapy. Patients with sufficient lesion uptake of \[68Ga\]Ga DOTA-5G PET/CT will be offered therapy. Patients will undergo a follow up \[68Ga\]Ga DOTA-5G PET/CT scans to assess tretament efficacy.

Trial Locations (1)

95817

RECRUITING

The University of California Davis Comprehensive Cancer Center, Sacramento

All Listed Sponsors
collaborator

National Institutes of Health (NIH)

NIH

lead

University of California, Davis

OTHER